InMed Pharmaceuticals (INM) Cash from Investing Activities Growth (1y) (2023 - 2024)
InMed Pharmaceuticals (INM) Cash from Investing Activities Growth (1y) (2023 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 100.00% |
| Jun 30, 2023 | 95.37% |
| Mar 31, 2023 | -3,508.16% |